Agilent Awards Trilogy Sciences with a Golden Ticket at LabCentral
May 12 2020 - 8:00AM
Business Wire
Sponsorship will enable advancements in cancer research
Agilent Technologies Inc. (NYSE: A) announces that biotech
startup Trilogy Sciences has been awarded an Agilent Golden Ticket
at LabCentral, a leading biotech innovation hub based in Cambridge,
Massachusetts. LabCentral is a shared laboratory space designed as
a launchpad for high-potential life sciences and biotech startups.
The Golden Ticket provides funding of one lab bench space for a
year.
Three semi-finalists, including Trilogy, presented their
proposals during a virtual online event on May 5, 2020. Trilogy was
chosen by a panel of judges consisting of Johannes Fruehauf, M.D.,
Ph.D., cofounder, and president of LabCentral; Darlene Solomon,
Ph.D., senior vice president, and chief technology officer at
Agilent; and Angelica Riemann, vice president of Agilent’s
Chemistries and Supplies Division.
“As part of Agilent and LabCentral’s shared commitment to
advancing health sciences and early-stage biotechnology companies,
we are thrilled to provide Trilogy with an Agilent Golden Ticket,”
said Darlene Solomon. “We wish to recognize each of the
semi-finalists for their stellar contributions to advancing
scientific research and innovation in their respective fields.”
"Agilent has an established reputation for being one of the most
innovative and collaborative partners in the chemical biology
field, and we are so excited to receive their support and
partnership as we aspire to build a series of lifechanging
therapeutics for untreatable diseases,” said Neil Dhawan, founder
of Trilogy Sciences.
“We are excited by Agilent’s ongoing support of LabCentral and
the Golden Ticket program,” said Fruehauf Johannes. “Golden Tickets
provide early-stage companies an excellent way to benefit from the
uniquely collaborative and supportive environment that LabCentral
offers, as well as the opportunity to work alongside other
entrepreneurs, scientists, and sponsors like Agilent.”
Trilogy Sciences’ mission is to develop life-changing
therapeutics for untreatable diseases by applying cutting-edge
chemical biology, including new methodologies to rapidly synthesize
and screen for hyper-effective drugs to combat recurrent breast,
brain, and lung cancers.
Agilent is a platinum sponsor of LabCentral and has equipped the
shared laboratory workspace with a variety of Agilent technology,
including a high-resolution mass spectrometry system, and a cell
analysis extracellular flux (XF) analyzer. The sponsorship includes
the Golden Ticket, which represents one year of bench space for a
scientist, including the benefit of LabCentral's shared
infrastructure and services.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. Now in its
20th year as an independent company delivering insight and
innovation toward improving the quality of life, Agilent
instruments, software, services, solutions, and people provide
trusted answers to customers' most challenging questions. The
company generated revenue of $5.16 billion in fiscal 2019 and
employs 16,300 people worldwide. Information about Agilent is
available at www.agilent.com. To receive the latest Agilent news,
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn,
Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200512005136/en/
Naomi Goumillout Agilent Technologies +1.781.266.2819
naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024